Quantum computing's potential for drug discovery: Early stage industry dynamics
Abstract
Quantum computing (QC) is expected to revolutionize the drug research by performing tasks classical that supercomputers are not capable of. However, practically useful quantum computation is not yet a reality, and thus it is still unclear when and whether QC will be fully capable of solving real-world issues in drug discovery. By identifying the QC-related activities of pharmaceutical companies, startups, and academia in the field of drug discovery and development, we show that QC has gained traction across all of these stakeholder groups, that there is focus on developing utilities related to lead optimization and compound screening, and that there is a need for collaboration in the highly dynamic QC ecosystem. Teaser: Quantum computing could potentially revolutionize {AuQ: Edit OK?} drug discovery and development, but pharmaceutical companies, startups and academia have had different responses to the promise offered by this novel yet immature technology.
Read the paper
Related studies
- Quantum dots: synthesis, bioapplications, and toxicity
- A Guide to In Silico Drug Design
- In silico toxicology protocols
- Automated in Silico Design of Homogeneous Catalysts
- In-silico strategies in nano-drug design: Bridging nanomaterials and pharmacological applications
- mRNA codon optimization with quantum computers
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.